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Abstract
Background: Hematopoietic stem cell transplant (HSCT) is the preferred treatment for young patients with multiple 
myeloma (MM), but for older adults there is limited evidence on its effectiveness from clinical trials.
Methods: We used the Surveillance, Epidemiology, and End Results (SEER)–Medicare database to identify individuals 
age 66 years and older with multiple myeloma (MM) who were diagnosed between 2000 and 2007. We used traditional 
multivariable analysis, propensity score–based analysis, coarsened exact matching, and an instrumental variable analysis 
to compare survival for individuals who did or did not receive an hematopoietic stem cell transplant. Survival was 
measured by Cox proportional hazard models. All statistical tests were two-sided.
Results: Patients with MM receiving an HSCT were more likely to be white, married, younger, and have fewer comorbidities. 
Results from all analytic techniques consistently showed that HSCT statistically significantly improved survival, with 
hazard ratios (HRs) ranging from 0.531 to 0.608 (traditional multivariable analysis: HR = 0.582, 95% confidence interval 
[CI] = 0.49 to 0.69; propensity score analysis: HR = 0.572, 95% CI = 0.46 to 0.72; coarsened exact matching: HR = 0.608, 95% 
CI = 0.49 to 0.76; instrumental variable analysis: HR = 0.531, 95% CI = 0.36 to 0.78, all P values ≤ .001).
Conclusions: Overall survival has increased among patients with MM receiving HSCT. This finding was consistent across 
statistical methods, indicating robustness of our findings.
Hematopoietic stem cell transplant (HSCT) is considered the 
preferred treatment for eligible patients with multiple myeloma 
(MM) (1,2). However, for older adults there is limited evidence 
from clinical trials. Currently, some European clinical guidelines 
do not recommend that patients over age 65  years receive a 
transplant; in contrast, US guidelines are less restrictive regard-
ing age (3). Recent studies have found that older adults are 
increasingly receiving HSCTs (4,5). This study aims to provide 
evidence on the real-world effectiveness of hematopoietic stem 
cell transplant for elderly patients.
There is little evidence that documents the real-world effec-
tiveness because of the small numbers of individuals who undergo 
transplantation. These studies generally show favorable results, 
but are typically based on small phase 2 studies and experience at 
individual centers, and use a case-control design (6–14). The find-
ings are further limited because of selection bias (transplant candi-
dates are healthier than rejected candidates) and because standard 
regression methods do not correct for unmeasured confounders.
Recently developed statistical methods can minimize selec-
tion bias. Matching techniques, including propensity scores and 











coarsened exact matching, directly adjust for confounding vari-
ables by matching patients with similar exposure to the treat-
ment of interest. These matching techniques can only address 
selection bias caused by characteristics that are observable in the 
data. However, instrumental variable analysis controls for both 
observable and unobservable characteristics by identifying an 
exogenous variable, known as an instrument, which is correlated 
with the treatment but not with the outcome. Researchers then 
capitalize on variations in the instrument to impute an unbiased 
estimate of the treatment’s causal effect on the outcome.
The objective of this study was two-fold. First, we assessed 
survival differences resulting from an HSCT among older indi-
viduals with MM. Second, we compared the performance of 
four analytic approaches. To address these aims, this study 
used observational claims data to compare the survival of MM 
patients who had an HSCT to survival among those patients 
who did not. We used traditional multivariable regression, pro-
pensity score matching, coarsened exact matching (CEM), and 
instrumental variable analysis to assess the effectiveness of 
transplant and the robustness of our results.
Methods
Data
We used the Surveillance, Epidemiology, and End Results (SEER)–
Medicare database for this analysis. SEER is a population-based 
cancer registry that covers 26% of the population and collects 
information on tumor characteristics and survival, as well as 
demographic information. Patients in the SEER are linked to 
their fee-for-service (FFS) Medicare claims. The Medicare data-
base includes data on patients with Medicare Part A (inpatient) 
and Part B (outpatient), including billed claims and services 
(15,16). The SEER-Medicare database has been shown to effec-
tively measure surgery, has been extensively used to measure 
use of surgical procedures, and has previously been used to 
measure use of HSCT among patients with acute myeloid leuke-
mia (15,17–20). More information on the SEER-Medicare data can 
be found in previous publications (15,16,21,22).
Clinical and Demographic Characteristics
The institutional review board approval was waived because 
SEER-Medicare data is deidentified administrative data with 
no personal identifiers. We selected individuals with MM 
diagnosed between October 1, 2000 and December 31, 2007 
and a valid recorded date of birth (n  =  22 287). We chose 
October 1, 2000 as the start date because Medicare started 
reimbursing for HSCT at this time and December 31, 2007 as 
the end date because it allowed us to follow patients for at 
least two years after diagnosis to assess survival. Patients 
were required to be between the ages of 66 and 80  years 
when diagnosed (n = 10 382). Included patients were required 
to have both Medicare Parts A  and B FFS coverage starting 
one year prior to diagnosis. Managed care enrollees were 
excluded because Medicare claims do not record their utiliza-
tion (n = 6831). We then identified patients as having received 
an HSCT if they had any of the following codes: International 
Classification of Disease-9 (ICD-9, 41.00, 41.01, 41.04, 41.07, 
41.09) or Healthcare Common Procedure Coding System 
(HCPCS, 38241). We limited our sample to patients who either 
had an HSCT or who lived at least six months after diagnosis 
to ensure that they would have lived long enough to have 
been offered a transplant (n = 4515).
Outcomes and Explanatory Variables
The primary outcome was all-cause mortality, defined as sur-
vival time from diagnosis until death or the end of the study 
period (December 31, 2010). We included age at diagnosis, 
comorbidity burden, sex, marital status, urban status, and race 
as explanatory variables. We calculated comorbidity burden 
using the Klabunde version of the Charlson Index using both 
inpatient and outpatient claims for 12 months prior to the date 
of diagnosis (23,24). The Klabunde adaptation modifies the 
Charlson Index to predict mortality for patients with cancer 
rather than the general population.
Statistical Analysis
We compared the characteristics of patients who did and did 
not undergo an HSCT using chi-squared tests for categorical 
variables and t tests for continuous variables. All statistical tests 
were two-sided, and P values of less than .05 were considered 
statistically significant. We then conducted an adjusted analysis 
using Cox regression for our four methodological approaches: 
1) standard multivariable regression in the unmatched cohorts, 
2)  propensity scored, matched analysis, 3)  coarsened exact 
matching analysis, and 4)  the instrumental variable analysis. 
Cox model proportionality assumptions were assessed using 
scaled Schoenfeld residuals. For all analyses, we calculated haz-
ard ratios with 95% confidence intervals.
Propensity scoring analysis controls for selection bias 
caused by observable characteristics. We calculated the pro-
pensity score using a logistic regression with the following vari-
ables: sex, race, age, comorbidity score, urban status, area level 
poverty (25), marital status, SEER reporting region, and year of 
diagnosis. Individuals were matched using a 1:1 nearest neigh-
bor approach with a 0.1 caliper without replacement (26); this 
approach eliminated 17 individuals who had an HSCT. We per-
formed several sensitivity analyses, varying the caliper and the 
number of matches.
Coarsened exact matching (CEM) is a relatively new tech-
nique (27,28). CEM is like propensity scoring in that it creates a 
group that did not receive the treatment of interest that is simi-
lar to the group that did receive the treatment (27). CEM matches 
case patients and control patients based on “coarsened” explan-
atory variable categories; in our analysis these included age, 
race, sex, marital status, urban status, comorbidity score, and 
year diagnosed. CEM then creates the explanatory variables 
strata. If a stratum does not include at least one case patient 
and one control patient, it is excluded. For this analysis, we per-
formed a 1:1 match and included only one control patient for 
every case patient. This procedure caused 12 individuals with-
out control patients in the same stratum to be dropped.
The instrumental variable (IV) analysis can adjust for both 
observed and unobserved characteristics, but depends on con-
struction of an appropriate exogenous instrument. To be con-
sidered an instrument, a variable must be correlated with the 
treatment but not with the outcome. As has been done in many 
other health services research studies, we used geographic var-
iation as our instrument (29–34). We created the IV in two steps, 
similar to the instrument used by Hadley et  al. and Wright 
et al. (29,30). In the first step, we used logistic regression to pre-
dict the probability of having an HSCT as a function of age, 
race, sex, marital status, urban status, area level poverty, and 
comorbidity score. In the second step, for each year and health 
service area (HSA), we calculated the difference between the 
observed and predicted number of transplants. This is a valid 











instrument for several reasons. First, there is statistically sig-
nificant variation across areas (F = 233, P = .002) and a strong 
association between receipt of treatment and location (F = 221, 
P < .001). Second, location should be independent of patient 
characteristics. We conducted the IV analysis using the two-
step residual inclusion method (35) with hazard rates being 
estimated in the second stage equation. We used bootstrap-
ping to construct standard errors and confidence intervals for 
the second-stage results.
Results
A total of 4515 patients with MM were diagnosed between 
October 1, 2000 and December 31, 2007, and 263 (5.8%) individu-
als had a transplant (Table 1, Figure 1). Median follow-up time 
was 32  months, and the mean age diagnosed was 72.7  years 
(range, 66–79 years). Table 1 provides descriptive characteristics 
for the patients stratified by receipt of a transplant. There were 
statistically significant differences between individuals who 
received an HSCT and those who did not. As shown in Table 1, 
transplanted individuals were more likely to be male, white and 
married, younger, from lower poverty areas, and to have been 
diagnosed earlier during the time period.
As shown in Table  1, for both matching methods (propen-
sity scoring and coarsened exact matching), matched cohorts of 
transplanted subjects and subjects who were not transplanted 
did not differ statistically with respect to any characteristics.
As shown in Table 2, all analytic techniques yielded consist-
ent results, indicating that an HSCT statistically significantly 
improves survival (Figure 2). As shown in Table 2, the traditional 
multivariable analysis found that among transplant recipients, 
survival improved (hazard ratio [HR]  =  0.582, 95% confidence 
interval [CI] = 0.49 to 0.69). Corresponding improvements esti-
mated by the other methods were similar, with a hazard ratio 
of 0.572 (95% CI = 0.46 to 0.72) for propensity score analysis, a 
hazard ratio of 0.608 (95% CI = 0.49 to 0.76) for coarsened exact 
matching, and a hazard ratio of 0.531 (95% CI = 0.36 to 0.78) for 
IV analysis (all P ≤ .001). All coefficients and standard errors are 
reported in Supplementary Table 1 (available online).
Discussion
This analysis showed that HSCT improves overall survival for 
older individuals with MM. Previously, the survival benefit of 
HSCT had been demonstrated primarily among younger indi-
viduals, with survival gains similar to those observed in older 
Table 1. Characteristics of observational, propensity score–matched and coarsened exact–matched patients
Characteristics













Age at diagnosis, y
 66–69 62 24 <.001 60 59 .72 61 61 1.00
 70–74 32 37 34 35 33 33
 75–80 6 39 6 6 6 6
Female 39 47 .01 40 44 .47 39 39 1.00
Race
 White 88 75 <.001 87 88 .73 88 82 .24
 Black/other 12 25 13 12 12 17
Marital status
 not married/ 
unknown
23 41 <.001 25 33 .08 23 23 1.00
 Married 77 59 75 67 78 78
Poverty, lowest to highest
 Quartile 1 30 22 <.001 30 29 .90 31 26 .21
 Quartile 2 26 23 27 29 26 22
 Quartile 3 22 24 21 18 21 26
 Quartile 4 15 25 15 18 15 21
 Missing 7 6 7 8 7 6
Urban/rural
 Big metro 61 54 .12 61 61 .98 61 54 .15
 Metro/urban 31 35 32 31 35 39




 0 63 60 .13 62 69 .30 65 64 .38
 1 24 20 24 18 23 23
 2+ 13 20 14 13 12 12
Year diagnosed
 2000–2001 24 21 <.001 22 23 1.00 22 22 1.00
 2002–2003 27 28 28 27 28 28
 2004–2005 32 27 32 33 33 32
 2006–2007 17 24 17 17 17 16
* Chi-squared tests were used for categorical variables and t tests for continuous variables. All statistical tests were two-sided.











patients (36). Furthermore, this study overcame many of the 
methodological challenges that have hindered previous studies 
by using sophisticated analytic methods and a nationally repre-
sentative dataset.
This analysis investigated whether in the real world older 
individuals also accrue the survival benefit associated with 
HSCT and addressed selection bias and confounding based on 
observable characteristics using propensity score analysis and 
CEM. Furthermore, we minimized bias from unobservable char-
acteristics using IV analysis.
In this study, we found that relatively few older individuals 
(5.8%) received an HSCT, using SEER-Medicare data. This low 
rate of transplantation may reflect the limited supply of can-
cer centers that are able to offer HSCT for older individuals. 
It is unclear if the supply of centers that offer HSCT in SEER 
reporting regions is generalizable to nonreporting regions, 
meaning that the national HSCT rate may be lower or higher 
than our estimate. Despite this limitation, this study suggested 
that many individuals may benefit if they were to receive a 
transplant.
Although it is clinically beneficial, this procedure is costly. 
Based on expected expenditures, HSCT would likely increase 
initial costs, but decrease costs in the years following trans-
plantation; that is, the high up-front cost may be made up for 
by lower costs in the long run. The cost-effectiveness literature 
has indeed found that HSCT is cost-effective, with a cost-effec-
tiveness ratio far under the conventional $100 000 per quality-
adjusted life-year upper threshold for value (6,37–41). In related 
work, we have found that this procedure is cost-effective in this 
population (42).
This study paid special attention to addressing methodolog-
ical challenges affecting previous research. First, because this 
study used a nationally representative dataset (SEER-Medicare), 
findings can be generalized to the broader US population 
with MM. Second, we used a variety of analytic approaches to 
assess the robustness of our results. Our multivariable regres-
sion allowed us to control for observable covariates. However, 
if observable characteristics vary substantially between treat-
ment groups, the regression may not adequately control for 
their influence (30). Matching methods, such as propensity 
scoring and CEM, address this situation by balancing observ-
able characteristics among patients who do and do not receive 
transplants. Finally, the IV methods address bias potentially 
introduced by unobservable characteristics that influence 
both treatment and outcome. For example, healthier patients 
are more likely to live and might be more likely to receive a 
risky treatment. In this case, even if the treatment does not 
affect outcome, the analysis results could indicate a positive 
association between treatment and survival (43). To develop 
an effective IV, a researcher must identify an instrument that 
influences treatment choice, but does not directly influence the 
outcome. Because the instrument acts as an explanatory vari-
able that breaks the causal link between potential confounders 
and the outcome, any association between the instrument and 
the outcome must be caused by the treatment. Because all four 
of the methods used in this paper produced similar effect esti-
mates, our analysis indicates that the result is robust against 
potential sources of bias.
We acknowledge a series of limitations. We were unable to 
observe discrete clinical characteristics in the administrative 
data, such as patient plasma cell burden, specific laboratory 
values (eg, hemoglobin, calcium, creatinine, and albumin), 
integrated prognostic markers (eg, beta2-microglobulin), tumor 
genetic factors (eg, loss of all or part of chromosome 13), or 
response to induction therapy. We recognize that these clinical 
factors influence a patient’s eligibility for receiving an HSCT 
and acknowledge this as a limitation of the study. However, we 
were able to overcome these unobserved confounders by using 
instrumental variables. We conditioned on patients living at 
least six months or receiving a transplant. Because this restric-
tion biases the results towards the null, the actual impact of 
transplant on survival may be even greater than what we have 
estimated. We acknowledge that our instrumental variable 
results depend on our having successfully created an exog-
enous instrument. It is possible that there is a relationship 
between HSA and overall survival; however, this relationship is 
unlikely. Furthermore, location has been used as an instrument 
in many studies (29–34). Additionally, the instrument passes all 
statistical tests. The IV analysis allows researchers to overcome Figure 1. Consort Diagram. SEER = Surveillance, Epidemiology, and End Results.
Table 2. Adjusted Cox proportional hazards models comparing survival of autologous transplant vs nontransplant stratified by analytic method*
Estimation method No. Adjusted HR (95% CI) P
Traditional regression 4515 0.582 (0.49 to 0.69) <.001
Propensity score–matched 492 0.572 (0.46 to 0.72) <.001
Coarsened exact–matched 504 0.608 (0.49 to 0.76) <.001
Instrumental variable 4515 0.531 (0.36 to 0.78) .001
* All statistical tests were two-sided. CI = confidence interval; HR = hazard ratio.











confounding caused by unobserved factors, but it complicates 
interpretation of the results. Specifically, we cannot identify all 
factors associated with treatments and outcomes to help guide 
clinical decision-making. Despite these limitations, the find-
ings suggest that older individuals do benefit from HSCT.
In summary, this study found a statistically significant sur-
vival benefit from HSCT for older individuals. These findings 
were robust across a variety of statistical methods. Given the 
strength of this result, its consistency across methods, and the 
fact that many patients over the age of 65 years are diagnosed 
with MM, clinical trials may be warranted to better understand 
the effectiveness of HSCT in older adults.
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